• A Company Dedicated to Safe Therapeutic Modulation of Monoamine Neurotransmitter

    Read more

  • Reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensin

    Read the press release

  • Annual report 2023

    May 2, 2024

    Read more

  • Interim Report January – March 2024

    May 10, 2024

    Read the report

  • Interim Report January – June 2024

    August 23, 2024

    Read the report

Press releases

Older releases

Latest reports

All reports

Calendar

All events

Share

Read more

Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiatorpharma-module-homepage-1-22102021

Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.

View our Pipeline

CEO letter

I am pleased to share an update on Initiator Pharma’s progress during the second quarter of 2024, a period marked by strategic advancements in our ongoing efforts to address unmet medical needs in erectile dysfunction (ED) and beyond.

Read the full letter
Initiatorpharma-module-homepage-2-22102021

Monoamine transporters is a unique class of proteins that are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. Our unique monoamine reupdate inhibitors are targeting the monoamine transporters to increase the levels of monoamine transmitters in diseases.

Read more about our technology